Document Detail


Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double-blind, placebo-controlled pilot study.
MedLine Citation:
PMID:  16368299     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Treatment of hypertension (HT) can reduce the risk for cardiovascular diseases. Tomato extract contains carotenoids such as lycopene, beta carotene, and vitamin E, which are known as effective antioxidants, to inactivate free radicals, and to slow the progression of atherosclerosis. The purpose of our study was to evaluate the effect of tomato extract on systolic and diastolic blood pressure in grade-1 HT, on serum lipoproteins, plasma homocysteine, and oxidative stress markers. METHODS: This study is a single-blind, placebo-controlled trial. Thirty-one subject with grade-1 HT, without concomitant diseases, who required no antihypertensive or lipid-lowering drug therapy, who were recruited from primary care clinics, completed the trial. Subjects entered a 4-week placebo period, then an 8-week treatment period with tomato extract, 250 mg Lyc-O-Mato, and a 4-week control period with placebo. RESULTS: Systolic blood pressure decreased from 144 (SE +/- 1.1) to 134 mm Hg (SE +/- 2, P < .001), and diastolic blood pressure decreased from 87.4 (SE +/- 1.2) to 83.4 mm Hg (SE +/- 1.2, P < .05). No changes in blood pressure were demonstrated during placebo periods. Thiobarbituric acid-reactive substances, a lipid peroxidation products marker, decreased from 4.58 (SE +/- 0.27) to 3.81 nmol/mg (SE +/- 0.32, P < .05). No significant changes were found in lipid parameters. CONCLUSIONS: A short-term treatment with antioxidant-rich tomato extract can reduce blood pressure in patients with grade-1 HT, naive to drug therapy. The continuous effect of this treatment and the long-term beneficial effect on cardiovascular risk factors still need to be demonstrated.
Authors:
Yechiel N Engelhard; Benny Gazer; Esther Paran
Related Documents :
6760679 - Antihypertensive and metabolic effects of increasing doses of atenolol and labetalol. a...
2892349 - Chronic 5-ht2-receptor blockade by ritanserin does not reduce blood pressure in patient...
1382159 - Twenty-four-hour ambulatory noninvasive continuous finger blood pressure measurement wi...
19840529 - The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients...
2885169 - Terazosin. a review of its pharmacodynamic and pharmacokinetic properties, and therapeu...
2655909 - Antihypertensive effectiveness of very low doses of hydrochlorothiazide: results of the...
15619409 - Relation of diurnal blood pressure variation and triglyceride-to-high-density lipoprote...
11268019 - Lower body negative pressure: a test of cardiovascular autonomic function.
9452149 - Effects of body position on the carbon monoxide diffusing capacity in patients with chr...
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  American heart journal     Volume:  151     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2005-12-21     Completed Date:  2006-03-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  100     Citation Subset:  AIM; IM    
Affiliation:
Hypertension Unit, Faculty of Health Sciences, Soroka University Medical Centre, Ben Gurion, University of the Negev, 84101 Beer Sheva, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antioxidants / therapeutic use*
Double-Blind Method
Female
Humans
Hypertension / drug therapy*
Lycopersicon esculentum*
Male
Middle Aged
Phytotherapy*
Pilot Projects
Plant Extracts / therapeutic use
Single-Blind Method
Chemical
Reg. No./Substance:
0/Antioxidants; 0/Plant Extracts

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan...
Next Document:  Identification of the ischemic etiology of heart failure by cardiovascular magnetic resonance imagin...